Zobrazeno 51 - 60
of 392
pro vyhledávání: '"35"'
Autor:
Martin Graversen, Sarah Cosyns, Wouter Willaert, Anne Hoorens, Wim Ceelen, Dries Reynders, Louis Sandra, Leen Van de Sande, An Vermeulen
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
4065 Background: Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) was recently introduced in the palliative treatment of peritoneal metastases (PM). Results from preclinical experiments suggest that intraperitoneal (IP) Nab-PTX may result
Autor:
Michèle Beniey, Takrima Haque, S. Hassan, Nelly Bechir, Danh Tran-Thanh, Alexia Cotte, Audrey Hubert
Publikováno v:
Journal of Clinical Oncology. 39:586-586
586 Background: PARP inhibitors (PARPi) such as talazoparib and olaparib, have demonstrated an improvement in progression-free survival (PFS) amongst metastatic HER2-negative breast cancer patients with germline mutations in BRCA1/2 (BRCA-MUT). Clini
Autor:
David M. Gershenson, Virginia Bayer, Neil S. Horowitz, Alexis Rabbit, Susana M. Campos, Shannon N. Westin, Lone Ottesen, Anil K. Sood, Pamela T. Soliman, Ying Yuan, Robert L. Coleman, Sobiya Tukdi, Alexi A. Wright, Panagiotis A. Konstantinopoulos, Gordon B. Mills, Robert Godin, Karen H. Lu, Charles F Levenback, Bryan Fellman, Joyce F. Liu
Publikováno v:
Journal of Clinical Oncology. 39:5505-5505
5505 Background: Wee1 phosphorylates and inhibits cyclin-dependent kinases 1 and 2 and is involved in regulation of the intra-S and G2/M cell cycle checkpoint arrest for premitotic DNA repair. The Wee1 inhibitor, adavosertib, has demonstrated activit
Autor:
Masato Nakamura, Masahito Kotaka, Yasutoshi Kuboki, Eiji Oki, Takayuki Yoshino, Jun Watanabe, Tetsuji Terazawa, Takashi Ohta, Hitoshi Ojima, Hiroki Hara, Yu Sunakawa, Soichiro Ishihara, Hiroya Taniguchi, Takako Eguchi Nakajima, Kuniaki Shirao, Yudai Shinohara, Toshiki Masuishi, Satoshi Morita
Publikováno v:
Journal of Clinical Oncology. 39:3507-3507
3507 Background: The efficacy of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) as a later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated in clinical trials. Therefore, we conducted a randomized phase 2/3 study
Autor:
Cristiano Ferrario, Aurelius Omlin, Julie N. Graff, Tony Elliott, Ulka N. Vaishampayan, Yves Fradet, Charles Schloss, A. J. Ten Tije, Johann S. de Bono, Winald R. Gerritsen, Christian Heinrich Poehlein, Scott T. Tagawa, Emmanuel S. Antonarakis, Cuizhen Niu, Raymond S. McDermott, Christopher J. Hoimes, Clara Hwang, Deepak Kilari, Ronald de Wit, Hiroji Uemura
Publikováno v:
Journal of Clinical Oncology. 39:5042-5042
5042 Background: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study to evaluate pembrolizumab (pembro) in mCRPC. A previous analysis of patients with RECIST-measurable (cohort 4 [C4]) or bone-predominant nonmeasurable (cohort 5 [C5]) disease wh
Autor:
Rolf Mahlberg, Henning Pelz, Stefan Fuxius, Manfred Welslau, Meinolf Karthaus, Florian Kaiser, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Volker Heinemann
Publikováno v:
Journal of Clinical Oncology. 39:3526-3526
3526 Background: Compared to placebo, trifluridine/tipiracil (FTD/TPI) significantly improved overall and progression-free survival in patients (pts) with pre-treated metastatic colorectal cancer (mCRC) in the phase III RECOURSE trial. Although time
Autor:
Stephen J. Freedland, Andrew Gaiser, Sheldon Kong, Jamie Partridge, Yuxian Du, Chunmay Fu, Sreevalsa Appukkuttan, Ashley Cha, Jacqueline Parkin
Publikováno v:
Journal of Clinical Oncology. 39:e18690-e18690
e18690 Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are often treated with concurrent medications for the management of comorbid conditions. This increases the risk of drug interactions which may lead to compr
Autor:
Meriem Koual, Mathilde Gisselbrecht, Laure Fournier, Anne-Sophie Bats, Elisabeth Ashton, J. Medioni, Henri Azaïs, Elena Paillaud, Benjamin Nicaise, Nicolas Delanoy, Marie-Aude Le Frère Belda, Soraya Mebarki, Stéphane Oudard
Publikováno v:
Journal of Clinical Oncology. 39:5546-5546
5546 Background: The EWOC-1 trial compared Carboplatin monotherapy (C mono) to two different Carboplatin + Paclitaxel (CP) regimens (weekly or 3-weekly) in vulnerable elderly patients treated for advanced ovarian cancers (OC). This study was closed p
Publikováno v:
Journal of Clinical Oncology. 39:144-144
144 Background: We have recently demonstrated that a salvage therapy with carboplatin plus weekly docetaxel is effective in docetaxel-refractory prostate cancer (PC) and interferes with testosterone biosynthesis (Reuter et al.; Oncol Res & Treat. 201
Autor:
Hideyasu Matsuyama, Masaki Shiota, Hiromi Kanji, Shin Egawa, Kojiro Tashiro, Shizuyo Horiyama, Jun Haginaka, Masatoshi Eto, Ryo Inoue
Publikováno v:
Journal of Clinical Oncology. 39:112-112
112 Background: Abiraterone (Abi) has been becoming a pivotal drug not only for metastatic castration resistant prostate cancer (mCRPC), but also for metastatic hormone sensitive prostate cancer (mHSPC). Abi is metabolized to delta-4 Abi (D4A), the s